Ascentage Pharma Group International (STU:36X) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:36X Ascentage Pharma Group International STU:36X
78 GF Score
Price €3.96
GF Value €4.81
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:36X
78GF Score
Ascentage Pharma Group International STU:36X
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ascentage Pharma Group International (STU:36X) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of €3.96 is trading 17.7% below its estimated GF Value™ of €4.81. GuruFocus considers Ascentage Pharma Group International to be Modestly Undervalued.

Key valuation signals for STU:36X:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €4.81 vs. price of €3.96 (17.7% below fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the STU:36X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
78GF Score

Get the complete analysis for STU:36X

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.96
Price
€4.81
GF Value